title: 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
authors.forename: Norbert
authors.initials: N
authors.lastname: Grzasko
authors.forename: Marek
authors.initials: M
authors.lastname: Hus
authors.forename: Sylwia
authors.initials: S
authors.lastname: Chocholska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Pluta
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszynska
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics*; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics; D005260:Female; D005784:Gene Amplification; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D011379:Prognosis; D013792:Thalidomide / Q000008:administration & dosage; D014178:Translocation, Genetic
chemical_list: D013792:Thalidomide